28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
Both AD and TDP/HS contribute to hippocampal volume loss in older-old persons, with TDP/HS more strongly associated with hippocampal volume than AD in Alzheimer dementia. 3 key findings →
Design: cohort study Participants: 232 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The FAD cortical signature appears to be similar to that described for sporadic AD. 5 key findings →
Design: longitudinal study Participants: 43 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
These figures reflect a decline in the number of caregivers compared with a decade earlier, as well as an increase in the amount of care provided by each remaining caregiver. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Over the coming decades, the aging of the baby boom generation is projected to result in an additional 10 million people with AD. 2 key findings →
Participants: 800,000 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The global burden associated with physical inactivity is substantial. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Donepezil has been shown to be well tolerated and to improve cognition and global function in patients with mild to moderately severe Alzheimer's disease (AD). 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Cardiovascular risk factors often cluster into a metabolic syndrome that may increase the risk of dementia. 2 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We found excellent evidence for the efficacy of six or more sessions of individual behavioral management therapy centered on the care recipient's behavior in alleviating caregiver symptoms both immediately and for up to 32 months. 4 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Post-mortem studies indicate that in ageing and Alzheimer's disease tau tangles deposit early in the transentorhinal cortex, a region located in the anterior-temporal lobe that is critical for object memory. 5 key findings →
Design: cross-sectional Participants: 18 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Interventions had, on average, a significant, small-to-moderate effect on the improvement of ability/knowledge, subjective well-being, burden, depression, and the caregiver's anxiety as well as symptoms of the care recipient. 2 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The following 2 regions for tau burden were identified: the entorhinal cortex, which exhibits early signs of tauopathy, and the inferior temporal region, which is more closely associated with AD-related pathologic mechanisms. 4 key findings →
Design: cross-sectional Participants: 133 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The prevalence of geriatric ACHD is substantial, although severe lesions remain uncommon. 1 key finding →
Design: cohort study Participants: 3,239 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The neuropsychologic test battery from the Uniform Data Set (UDS) of the Alzheimer's Disease Centers (ADC) program of the National Institute on Aging consists of brief measures of attention, processing speed, executive function, episodic memory, and language. 2 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Dementia rates varied over 60% between groups, providing a comprehensive benchmark for the NAPA goal of reducing disparities. 2 key findings →
Participants: 18,778 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
At the beginning of June 2020, there were nearly 7 million reported cases of coronavirus disease 2019 (COVID-19) worldwide and over 400,000 deaths in people with COVID-19. 1 key finding →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Dementia emerged as the most potent risk factor for institutionalization in this 12-year community-based epidemiological study. 3 key findings →
Design: longitudinal study Participants: 1,147 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Future well-designed longitudinal researches examining the direct and indirect relationship between tooth loss and dementia risk are encouraged. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
These findings on participants who are at high risk of dropout may be useful in the planning phase of future prospective studies. 4 key findings →
Design: longitudinal study Participants: 5,278 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Although the association between high blood pressure (BP), particularly in midlife, and late-life dementia is known, less is known about variations by race and sex. 5 key findings →
Design: cohort study Participants: 2,003 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
These findings suggest that cerebrovascular disease may play an important role in determining the presence and severity of the clinical symptoms of AD. 5 key findings →
Participants: 61 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Cerebral microbleeds (CMBs) are increasingly recognised neuroimaging findings in individuals with cerebrovascular disease and dementia, and in normal ageing. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A projected 450,000 older Americans with AD will die in 2013, and a large proportion will die as a result of complications of AD. 1 key finding →
Participants: 200,000 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
All indicators of atherosclerosis were associated with dementia (odds ratios ranging from 1.3 to 1.9) and its major subtypes Alzheimer's disease (odds ratios 1.3-1.8) and vascular dementia (odds ratios 1.9-3.2). 4 key findings →
Participants: 284 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Persistence with statin therapy in older patients declines substantially over time, with the greatest drop occurring in the first 6 months of treatment. 1 key finding →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The data suggest that engagement in leisure activities may reduce the risk of incident dementia, possibly by providing a reserve that delays the onset of clinical manifestations of the disease. 4 key findings →
Participants: 1,772 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →